Walleye Capital’s AC Immune ACIU Stock Holding History

Walleye Capital’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-58,508	Closed	-$393	–	2068
2021 Q3	$393	Buy	+58,508	New	+$419K	0.01%	893

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Walleye Capital's ACIU Position: Q4 2021 in Review

Walleye Capital sold out of AC Immune (ACIU) in Q4 2021, closing a stake of 58,508 shares — an estimated $393 sold.

Walleye Capital first reported a position in ACIU in Q3 2021 and held it in 1 quarter. The position peaked at $393 in Q3 2021. 44 funds tracked by Wall St. Rank hold ACIU as of Q4 2021.

Walleye Capital reported no remaining AC Immune position as of Q4 2021 after selling out during the quarter.
Walleye Capital sold 58,508 AC Immune shares in Q4 2021, an estimated $393.
Walleye Capital first reported a position in AC Immune in Q3 2021 and held it in 1 quarter.
Walleye Capital's AC Immune position peaked at $393 in Q3 2021.
44 funds tracked by Wall St. Rank held AC Immune as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.